Revvity, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Weak

Quality Weak

Valuation Weak

Balance sheet Very weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Revvity, Inc., formerly known as PerkinElmer, Inc., is a global company based in Waltham, Massachusetts, that develops and delivers products, services, and solutions for the diagnostics, life sciences, and applied services sectors. Its Discovery & Analytical Solutions division offers advanced instrumentation, reagents, informatics, software, subscriptions, and detection and imaging technologies to support scientific research and environmental health assessments. The company also provides analytical tools for agricultural, food, and industrial markets, including sectors such as chemicals, semiconductors, and energy. Revvity's Diagnostics segment focuses on early detection, supplying instruments, reagents, assay platforms, and software for genetic disorder and infectious disease testing, as well as technologies for genomic workflows and drug discovery. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, healthcare organizations, medical professionals, and government bodies.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC3.3%Model input; read with the evidence status and period context.

Operating margin12.4%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years-7.1%Model input; read with the evidence status and period context.

FCF margin17.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.